Hepatoblastoma
Prepared with OnCo (onco.cc/prep/hepatoblastoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
16 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Serum AFP, PRETEXT / POST-TEXT group and annotation factors, CHIC risk group, CTNNB1 mutation, NFE2L2, TERT, Germline APCand 11p15), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (very low / standard risk (pretext i-iii, resectable, afp >100)), which of the standard options do you recommend and why?
- 6.Am I a candidate for Cisplatin, Sodium thiosulfate (otoprotectant), and what side effects should I expect?
- 7.For my situation (high risk (metastatic, afp <100, pretext iv, vascular involvement)), which of the standard options do you recommend and why?
- 8.Am I a candidate for Cisplatin, Doxorubicin, Vincristine or related drugs, and what side effects should I expect?
- 9.For my situation (unresectable after chemotherapy (post-text iv, central vascular involvement)), which of the standard options do you recommend and why?
- 10.For my situation (relapsed/refractory), which of the standard options do you recommend and why?
- 11.Am I a candidate for Irinotecan (and liposomal irinotecan), and what side effects should I expect?
- 12.Are there clinical trials I could join, for example of Sodium thiosulfate (otoprotectant), Liver transplantation for cancer (Milan criteria and beyond)?
- 13.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 14.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 15.I read that “Metastatic and low-AFP disease”. How does that affect my plan?
- 16.I read that “Long-term effects of cisplatin (hearing, kidney) and doxorubicin (heart)”. How does that affect my plan?
The words I may hear
- Alpha-fetoprotein (AFP): Alpha-fetoprotein is a protein made by the fetal liver that a substantial share of hepatocellular carcinomas switch back on.
Tests and results to bring
Biomarker results to ask for: Serum AFP (diagnosis, response, relapse; <100 ng/mL poor), PRETEXT / POST-TEXT group and annotation factors (V, P, E, M, R), CHIC risk group (age, AFP, PRETEXT, metastases), CTNNB1 mutation, NFE2L2, TERT, Germline APC (FAP) and 11p15 (Beckwith-Wiedemann).
Scans and tests linked to this cancer: HCC surveillance in cirrhosis (ultrasound + AFP), Ultrasound.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Very low / standard risk (PRETEXT I-III, resectable, AFP >100): Upfront resection for PRETEXT I-II (COG) or cisplatin monotherapy ×4-6 with delayed resection (SIOPEL-3); sodium thiosulfate after each cisplatin dose for otoprotection. (Cisplatin, Sodium thiosulfate (otoprotectant))
- High risk (metastatic, AFP <100, PRETEXT IV, vascular involvement): Cisplatin-doxorubicin (PLADO) or dose-dense cisplatin (SIOPEL-4), resection of primary and lung metastases; consider C5VD (COG). (Cisplatin, Doxorubicin, Vincristine, Fluorouracil (5-FU))
- Unresectable after chemotherapy (POST-TEXT IV, central vascular involvement): Orthotopic liver transplantation (5-year survival ~80%); early referral to a transplant centre. (Liver transplantation for cancer (Milan criteria and beyond))
- Relapsed/refractory: Irinotecan-based salvage, surgery for isolated recurrence, transplant if liver-confined; trials. (Irinotecan (and liposomal irinotecan), Liver transplantation for cancer (Milan criteria and beyond))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.